US 12,454,549 B2 · Treatments for diseases and disorders that involve oxidative stress

Abstract

Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.

Claims5

Dependent claims

An isolated, synthetic hexapeptide compound consisting of Gly-Arg-Gly-Cys-Thr-Pro (SEQ ID NO:6).

Dependencies are inferred from the claim text.

Facts

Application

18/206,415Filed 6 Jun 2023 · continuation in part

Priority

19 Jun 2017

Published

US 2024/0132542 A125 Apr 2024

Granted

28 Oct 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 5/06026
And aliphatic: the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 31/185
Medicinal preparations containing organic active ingredients: acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic…
A61K 38/05
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: dipeptides

Family

Application62/521,984Us provisional application · filed 19 Jun 2017

Application16/012,706Parent of this division · filed 19 Jun 2018

Application16/882,656Parent of this continuation-in-part · filed 25 May 2020

Application63/350,373Us provisional application · filed 8 Jun 2022

US 2024/0132542 A1Pre-grant publication · published 25 Apr 2024

Application16/882,656Parent of this division

US 2019/0062371 A1Published application

US 2020/0392181 A1Published application

US 12,454,549 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.

Facts

Application

18/206,415Filed 6 Jun 2023 · continuation in part

Priority

19 Jun 2017

Published

US 2024/0132542 A125 Apr 2024

Granted

28 Oct 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 5/06026
And aliphatic: the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 31/185
Medicinal preparations containing organic active ingredients: acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic…
A61K 38/05
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: dipeptides

Family

Application62/521,984Us provisional application · filed 19 Jun 2017

Application16/012,706Parent of this division · filed 19 Jun 2018

Application16/882,656Parent of this continuation-in-part · filed 25 May 2020

Application63/350,373Us provisional application · filed 8 Jun 2022

US 2024/0132542 A1Pre-grant publication · published 25 Apr 2024

Application16/882,656Parent of this division

US 2019/0062371 A1Published application

US 2020/0392181 A1Published application

US 12,454,549 B2This patent

From the US filing history. Foreign family members aren’t listed.

Treatments for diseases and disorders that involve oxidative stress

Life of this patent

Abstract

Claims5

Treatments for diseases and disorders that involve oxidative stress

Life of this patent

Abstract

Claims5